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Abstract
Dose-nding studies are frequently conducted to evaluate the eect of dierent doses
or concentration levels of a compound on a response of interest. Applications include
the investigation of a new medicinal drug, a herbicide or fertilizer, a molecular entity, an
environmental toxin, or an industrial chemical. In pharmaceutical drug development, dose-
nding studies are of critical importance because of regulatory requirements that marketed
doses are safe and provide clinically relevant ecacy. Motivated by a dose-nding study in
moderate persistent asthma, we propose response-adaptive designs addressing two major
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challenges in dose-nding studies: uncertainty about the dose-response models and large
variability in parameter estimates. To allocate new cohorts of patients in an ongoing study,
we use optimal designs that are robust under model uncertainty. In addition, we use
a Bayesian shrinkage approach to stabilize the parameter estimates over the successive
interim analyses used in the adaptations. This allows us to calculate updated parameter
estimates and model probabilities that can then be used to calculate the optimal design
for subsequent cohorts. The resulting designs are hence robust with respect to model
misspecication and additionally can eciently adapt to the information accrued in an
ongoing study. We focus on adaptive designs for estimating the minimum eective dose,
although alternative optimality criteria or mixtures thereof could be used, enabling the
design to address multiple objectives. In an extensive simulation study, we investigate the
operating characteristics of the proposed methods under a variety of scenarios discussed by
the clinical team to design the aforementioned clinical study.
Keywords: Dose-response; Drug development; Minimum eective dose; Optimal design; Shrink-
age approach.
1 Introduction
Dose-nding studies have several challenges in common. First, they usually address two distinct
objectives, which lead to dierent requirements on the study design (Ruberg (1995); Bretz, Hsu,
Pinheiro & Liu (2008)): (i) assessing whether there is any evidence of a drug eect, and (ii)
estimating relevant target doses. Second, the dose-response relationship is unknown prior to the
study, leading to model uncertainty. This problem is often underestimated, although ignoring
model uncertainty can lead to highly undesirable eects (Chateld (1995), Draper (1995), Hjorth
(1994)). Third, data from dose-nding studies are usually highly variable. This of particular
importance in pharmaceutical drug development, because sample sizes are kept to a minimum
for ethical and nancial reasons. It is therefore critical to develop ecient dose-nding study
designs that use the limited information as eciently as possible, while addressing the above
challenges.
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Many approaches have been proposed in the optimal design literature to distribute patients
eciently with regard to given study objectives, see Wu (1988), Fedorov & Leonov (2001) and
King & Wong (2004) among many others. However, most of this work has concentrated on an
assumed xed dose-response model. As there is typically considerable model uncertainty at the
planning stage of a dose-response study, these methods have limited practical use. Based on
concepts introduced by Lauter (1974) (see also Cook & Wong (1994), Zhu & Wong (2000), Zhu
& Wong (2001), Biedermann, Dette & Pepelyshev (2006)), Dette, Bretz, Pepelyshev & Pinheiro
(2008) investigated model-robust designs that provide ecient target dose estimates for a set of
candidate dose-response models, rather than for a single dose-response model. However, their
designs require knowledge about the unknown parameters associated with the anticipated dose-
response models as well as the pre-specication of model probabilities.
A natural remedy is to investigate response-adaptive designs (adaptive designs, in short) with
several cohorts of subjects. After each stage the accumulated information of the ongoing study is
used to update the initial information of the underlying model parameters and model probabili-
ties, which in turn is used to calculate the design for the subsequent stage(s). Several adaptive
designs have been developed for this problem; see, for example, Miller, Guilbaud & Dette (2007)
and Dragalin, Hsuan & Padmanabhan (2007) for recent approaches using optimal design theory,
or Zhou, Joseph, Wolfson & Belisle (2003), Muller, Berry, Grieve & Krams (2006), and Wa-
then & Thall (2008) for recent Bayesian adaptive designs. Dragalin, Bornkamp, Bretz, Miller,
Padmanabhan, Patel, Perevozskaya, Pinheiro & Smith (2010) performed an extensive simulation
study that compared ve dierent adaptive dose-nding methods.
In this paper we propose adaptive designs addressing the three major challenges described above:
multiple study objectives, model uncertainty and large variability in the data. For this purpose we
use the model-robust designs proposed by Dette et al. (2008) together with a Bayesian shrinkage
approach to stabilize the parameter estimates, especially in the early part of a study. This
allows one to calculate parameter estimates as well as model probabilities that can then be used
to calculate model-robust designs for the subsequent stage(s) of the study. The resulting designs
are robust with respect to model misspecication and additionally adapt to the continuously
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accrued information in an ongoing study. We focus on adaptive designs for estimating the
minimum eective dose (MED), i.e. the smallest dose achieving a clinically relevant benet over
the placebo response. However, alternative optimality criteria or mixtures of optimality criteria
could be used, enabling the design to address multiple objectives.
2 Asthma dose-nding study
The research for this article was motivated by a Phase II dose-nding study for the development
of a new pharmaceutical compound in asthma. This was a multi-center, randomized, double-
blind, placebo controlled, parallel group study in patients with moderate persistent asthma, who
were randomized to one of seven active dose levels or placebo. The primary endpoint was a
lung function parameter (forced expiratory volume in 1 second, FEV1) measured after 28 days
of administration, scaled such that larger values indicated a better outcome. The objective of
the trial was to evaluate the dose eects over placebo for the primary endpoint and to assess
whether there was any evidence of a drug eect. Once such a dose-response signal had been
detected, one would subsequently estimate relevant target doses, where the primary focus was
on estimating the MED.
Based on discussions with the clinical team, a homoscedastic normal model was assumed for
the primary endpoint with a standard deviation of 350 mL, a placebo eect of 100 mL and a
maximum treatment eect of 300 mL within the dose range [0, 50] under investigation. The
available doses were 0 (= placebo), 0.5, 1.0, 2.5, 5, 10, 20, and 50. The clinically relevant benet
over the placebo eect was set to 200 mL. That is, an increase in treatment eect of less than 200
mL over the observed placebo response was considered to be clinically irrelevant. Furthermore,
all dose levels within the investigated dose range were considered safe based on previous studies,
so that ecacy was of primary interest.
Because this study was conducted early in the drug development program, limited information
about the dose-response shape was available at the planning stage. A set of candidate dose-
response models was derived before starting the study, see Table 1 and Figure 1 for the full model
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specications (including a preliminary specication of the model parameters). Two concave
increasing models (Emax1, Emax2) were included to describe an increase of the dose-response
curve in the lower part of the investigated dose range. In addition, S-shaped (Logistic1), unimodal
(Beta) and convex (Logistic2) models were included in the candidate model set to robustify the
statistical analysis with respect to model uncertainty. We refer to Pinheiro, Bornkamp & Bretz
(2006) for details on the use of candidate models in dose-response studies and the elicitation of
best guesses for the model parameters.
Model Full model specication Model parameters True MED
Beta 0 + 1B(2; 3)(d=60)
2(1  d=60)3 (100, 300, 0.43, 0.6) 5.21
Emax1 0 + 1d=(2 + d) (100, 420, 20) 18.18
Emax2 0 + 1d=(2 + d) (100, 330, 5) 7.69
Logistic1 0 + 1= f1 + exp[(2   d)=3]g (98, 302, 17.5, 3.3) 19.82
Logistic2 0 + 1= f1 + exp[(2   d)=3]g (92, 615, 50, 11.5) 42.28
Table 1: Candidate dose response models as a function of dose d, where B(a; b) = (a +
b)a+b=(aabb).
Given the information and constraints above, the clinical team was faced at the planning stage
with several remaining key questions on the study design:
(A) Should an adaptive design be employed at all or would a non-adaptive design be sucient?
(B) If the decision was to employ an adaptive design, how many interim analyses should be
conducted?
(C) How many dose levels should be included in the study, i.e. are all seven active dose levels
from above needed?
(D) If not all active dose levels were needed, which of them should then be investigated?
In addition to these statistical questions, many further considerations were discussed by the
clinical team: adaptive designs require more logistical eort to set-up the repeated data collection
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Figure 1: Graphical display of the dose-response models in Table 1. Open dots denote the potential
responses at the seven active dose levels and placebo available in the study. Dotted horizontal
lines indicate the clinical relevance threshold on top of placebo response and dotted vertical lines
the resulting MED.
and cleaning/analysis processes than non-adaptive designs; including all seven active doses in
the study would pose serious challenges to the drug manufacturing and supply departments,
especially if the allocation changed during the study course; and how to ensure trial integrity
and validity. In the following we focus on the statistical questions and describe the proposed
methodology that was nally implemented in the study.
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3 Methodology
Assume k distinct dose levels d1; : : : ; dk, where d1 = 0 denotes placebo. Let ni patients be
allocated to dose di and N =
Pk
i=1 ni. The vector of allocation weights is denoted by w =
(w1; : : : ; wk)
0, where wi = ni=N . Let further Yij  N(f(di;); 2) denote the observation of
patient j = 1; : : : ; ni at dose di; i = 1; : : : ; k, where the dose-response model f(:) is parameterized
through the parameter vector  and N(; 2) denotes the normal distribution with mean  and
variance 2.
Most dose-response models used in practice, including those in Table 1, can be decomposed as
f(d;) = 0 + 1f
0(d;0); (1)
where  = (0; 1;
00)0 = (0; : : : ; p)0. The parameters 
 = (0; 1)0 enter the model function
f linearly and determine its location and scale, while f 0 is typically a non-linear function that
determines the shape of the model function f through the parameters 0.
The minimum eective dose producing a clinically relevant eect  over the placebo response is
dened as
MED = min
d2(d1;dk]
ff(d;) > f(d1;) + g; (2)
where we assume that a benecial eect is associated with larger values of the response variable.
Note that the MED may not exist, as no dose in (d1; dk] may produce an improvement of 
compared with placebo.
3.1 Robust designs for MED estimation
Given a function f 0, it follows from (2) that the MED (provided it exists) is a solution to
0 + 1f
0(0;0) +  = 0 + 1f
0(MED;0): (3)
Consequently, MED = b() = h0(f0(0;0) +=1), where h
0(x) = inffzjf 0(z)  xg denotes the
(generalized) inverse of the function f 0 with respect to the variable d. Standard asymptotic the-
ory for non-linear models (Seber &Wild 1989) yields that the maximum likelihood (ML) estimate
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b is approximately multivariate normal distributed with mean vector  and covariance matrix
2
N
M 1(;w); where M (;w) =
Pk
i=1wig(di;)g(di;)
0 denotes the information matrix and
g(d;) = @f(d;)
@
the gradient of the dose-response model f with respect to . It follows from the -
method (van der Vaart 1998) that the MED estimator based on b, [MED = b(b), is asymptotically
normally distributed with mean b() and variance V (;w) = 
2
N
rb()0M 1(;w)rb(), where
rb() = @b()
@
. Hence, minimizing V (;w) with respect to w 2 Sk = fwjPki=1wi = 1;w  0g
results in optimal designs that minimize the approximate variance of [MED. This design crite-
rion has also an appealing decision theoretic justication: The asymptotic normal distribution
of [MED approximates the posterior distribution of the MED in a Bayesian model framework.
Hence, minimizing the log-variance of [MED is equivalent to minimizing the (approximate) Shan-
non entropy of the posterior distribution of the MED (Chaloner & Verdinelli 1995).
In principle, the above optimization could be done with respect to the number and choice of doses
and their corresponding allocation ratios (Dette et al. (2008)), but in practice manufacturing
constraints often determine the available doses, as it was the case in the asthma study from
Section 2. In the following we thus restrict the optimization to the weights w for pre-specied
doses d1; : : : ; dk.
The true dose-response function f is unknown and optimal designs are typically not robust with
respect to model misspecication (Dette et al. (2008)). In the following we assume a set of M
candidate models fm(d;m) = 0m + 1mf
0
m(d;
0
m), m = 1; : : : ;M , such as those described in
Table 1. We \integrate" the design criterion conditional on model m with respect to the model
probabilities m. Hence, using the design criterion
PM
m=1 m log(Vm(m;w)) or, equivalently,
	(w) =
MY
m=1
(Vm(m;w))
m (4)
leads to designs that are robust with respect to model misspecication, where Vm(m;w) denotes
the variance of the estimate for the MED in themth model (m = 1; : : : ;M). Note that because of
taking logarithms above there is no need to standardize the individual model variances. However,
the numerical calculation of robust designs using the criterion (4) requires the knowledge of m
and m;m = 1; : : : ;M . In the following sections we describe how the initial best parameter
guesses can be updated during an ongoing study such that subsequent stages can be re-designed
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based on the updated estimates for m and m;m = 1; : : : ;M ; see Section 3.3 for a description
of the complete procedure in an algorithmic form.
3.2 Updating of model parameters and weights
Reliably estimating the parameters 1; : : : ;M is a challenging problem, particularly in early
stages of a study. ML estimates for these parameters are typically highly variable, and may even
not exist without imposing bounds on the parameter space. One way of stabilizing estimates is
to use a shrinkage approach based on, for example, penalized maximum likelihood or maximum
a-posteriori (MAP) estimates. Here, one optimizes the log-likelihood function plus a term which
determines the prior plausibility of the parameters (the log prior distribution). The estimate
is then a compromise between the information contained in data and the prior distribution.
This stabilizes the estimates in early stages due to the shrinkage towards a-priori reasonable
values. In later stages the shrinkage eect decreases because the log prior remains constant
while the log likelihood receives more weight with increasing sample sizes. If a completely at
prior distribution is used, standard ML and MAP estimation coincide, so that using non-uniform
priors is desirable. We discuss the choice of non-uniform priors in more detail further below.
Apart from stable parameter estimates 1; : : : ;M for the dose-response models, one needs to
update the model probabilities 1; : : : ; M at an interim analysis. We propose using a probability
distribution over the dierent dose-response models and evaluating the posterior probabilities for
each model after having observed the data; see, for example, Kass & Raftery (1995) for a detailed
description of posterior probabilities and Bayes factors. These posterior model probabilities can
then be used in the design criterion (4). A computationally ecient approach to approximate
the posterior model probabilities is the Bayesian information criterion (BIC). However, previous
simulation studies in the context of dose-nding studies showed that the BIC approximation
frequently favors too simplistic models for realistic variances and sample sizes (Bornkamp 2006).
Other approximate methods, such as fractional Bayes factors, (O'Hagan 1995) or intrinsic Bayes
factors (Berger & Pericchi 1996) either depend on arbitrary tuning parameter values or are
computationally prohibitive. Thus, for each model we will use the exact posterior probabilities
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resulting from the prior distributions assumed for the MAP estimation. In our case, these
probabilities can be calculated using ecient numerical quadrature without the need to resort
to computationally expensive Markov Chain Monte Carlo techniques. In the remainder of this
section we provide details on the prior elicitation and the calculation of posterior probabilities.
3.2.1 Selection of prior distributions for m
We utilize the factorization in (1) to derive a prior distribution for (0m; 1m;
0
m; 
2). If 0m were
known, the non-linear models would reduce to a linear model. It is therefore reasonable to use
for a given 0m the conditionally conjugate normal-inverse gamma (NIG) distribution
p(m; 
2j0m) / (2) (d+4)=2 exp[ f(m   )0V  1(m   ) + ag=(22)]
for (m; 
2) (O'Hagan & Forster 2004), where a; d > 0,  2 R2 and V 2 R22 denotes a positive
denite matrix. The NIG distribution marginally induces a bivariate t-distribution for m with
d degrees of freedom, nite mean  and covariance matrix a=(d   2)V , provided that d > 2.
The marginal prior distribution for 2 is given by an IG distribution with mode a=(d+2), mean
a=(d   2) and variance 2a2=f(d   2)2(d   4)g. It has a nite mean when d > 2 and a nite
variance when d > 4.
To set up the NIG distribution for (m; 
2) one can employ available information about the
placebo eect, the maximum treatment eect and the standard deviation. For example, one
can choose the marginal bivariate t-distribution for m (conditional on 
0
m) such that the desired
mean and covariance are achieved for the placebo eect and the maximum eect of the underlying
dose-response model. When the linear parameters m cannot be interpreted as placebo and
maximum eect, one can use a suitable transformation to achieve the desired moments. Then,
one can adjust a and d so that the marginal distribution of 2 achieves the desired mode. An
attractive choice is to use d = 4, leading to a prior with innite variance for 2 and a heavy
tailed marginal prior for m.
For the non-linear parameters 0m, we propose selecting suitable bounds for the parameters and
then eliciting a bounded prior distribution. This is typically not dicult, as the interpretation
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Figure 2: Beta priors on [0.5,75] with mode 20 and dierent S values.
of the non-linear parameters is straightforward, and excessively large parameter values usually
correspond to a-priori unlikely model shapes. We propose using a scaled beta distribution B(; )
with mode equal to the initial parameter guesses. The curvature of the prior determines the
amount of shrinkage that one is willing to employ for the MAP estimates. In the simulations we
used the sum S = + as a measure of curvature with S > 2 to ensure unimodality of the beta
distribution. Note that already relatively small values of S, such as S = 10 or S = 20, lead to
strong shrinkage eects, see Figure 2 for an illustration of the 2 parameter in the Emax1 model,
where the initial parameter guess is 20. For dose-response models with more than one non-linear
parameter, we repeat this procedure for all parameters and assume independence among them.
For selecting prior model probabilities, it is convenient to use a uniform distribution across the
models unless some models are deemed a-priori more plausible than others.
3.2.2 Calculation of posterior probabilities
Let y denote the data available at an interim analysis and p(yjm;m) the likelihood under model
m with corresponding prior distribution p(mjm) and prior model probability p(m). Then the
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marginal likelihood is given by
p(mjy) / p(m)
Z
p(yjm; 2;m)p(m; 2jm) d(m; 2)
= p(m)
Z Z
p(yjm; 2;m)p(m; 2j0m;m) d(m; 2)p(0mjm) d0m:
The inner integral in the last equation is the product of a likelihood and a conjugate prior
distribution. One can hence reduce the integration to
p(mjy) / p(m)
Z
p(yj0m;m)p(0mjm) d0m; (5)
where p(yj0m;m) now denotes the integrated likelihood. In our applications, the integral (5) is
one- or two-dimensional over a bounded region and hence straightforward to calculate numeri-
cally. This allows us to calculate the marginal likelihoods eciently, without resorting to Markov
Chain Monte Carlo calculations, see Section 3.4 for details. The posterior model probabilities
can be obtained by normalizing the marginal likelihoods in (5) by their sum.
We use the maximum ~
0
m of the marginal posterior p(yj0m;m)p(0mjm) as an estimate of 0m.
Conditional on this value, we use the maximum ~

m of p(

mj~
0
m;y;m) as an estimate for 

m.
Therefore, the overall estimate of the parameter m is given by ~m = (~

m;
~
0
m). This is a slight
variation of the MAP approach described above, but reduces further the computational eort as
it re-uses the calculations from the integration to obtain the marginal likelihoods.
3.3 Main algorithm
We now summarize the complete response-adaptive dose-nding design in algorithmic form.
Before Trial Start
1. Select a starting design using either a balanced allocation across the available doses or an
unbalanced allocation based on optimal design considerations.
2. Select candidate dose-response models fm(d;m).
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3. Conditional on 0m, calculate a NIG prior distribution for (

m, 
2) based on \best guesses"
for the placebo eect, the maximum treatment eect and 2 (together with suitable vari-
ability assumptions for both parameters).
4. Choose \best guesses" for the non-linear parameters 0m and select the parameter S.
5. Choose prior model probabilities p(m) for the dierent dose-response functions.
At Interim Analysis
1. Calculate posterior model probabilities
p(mjy) / p(m)
Z
p(yjm;m)p(mjm)dm: (6)
Exploiting the conjugacy properties of the NIG distribution, this reduces to one- or two-
dimensional integrals, see Section 3.4 for details.
2. For each dose-response model, estimate m by using the maximum of p(yj0m;m)p(0mjm),
where the abscissas calculated in step 1 can be re-used. Conditional on this value, use the
maximum of p(mj~
0
m;y;m) as an estimate for 

m to obtain
~m
3. Plug the obtained parameter estimates ~m into (4) and set m = p(mjy). Then, minimize
with respect tow 2 S, where S = fw 2 Skjw = (nold+Nnextwnext)(Nold+Nnext) 1;wnext 2
Skg. Here, nold denotes the vector of sample sizes per dose and Nold the total sample size
until the current interim analysis. Further, Nnext denotes the sample size and wnext 2 Sk
the design weights for the next cohort of patients. We therefore optimize the design for
the next stage taking into account the patient allocation until the current interim analysis,
see Section 3.4 for computational details.
4. Allocate the next cohort of patients according townext by applying an appropriate rounding
technique, such as described in Pukelsheim (1993, ch. 12).
Note that the Bayesian approach is used here for design adaptation purposes. The nal analysis
may or may not be done using a fully Bayesian approach. The development of the Bayesian design
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methodology above is motivated by the MCP-Mod methodology described in (Bretz, Pinheiro
& Branson 2005) to address model uncertainty. This method requires prior estimates for the
placebo eect, the maximum treatment eect, and 2 at the design stage and \best guesses" of
the non-linear parameters 0m for the analysis. The additional information needed to set up the
above adaptive design procedure is hence minimal. Obviously, any other strategy that allows
one to use a set of candidate dose-response models might also be used for the nal analysis.
3.4 Technical details
In this section we provide further details of the algorithm presented above.
For the calculation of the one- and two-dimensional integrals in (5) we used quasi-uniformly
distributed point sets based on good lattice points u1; : : : ;un, where ui 2 [0; 1]d and d is the
dimension of 0m; see Fang & Wang (1994) for details on the construction of such integration
grids. Let (0mjy) = p(yj0m;m)p(0mjm) denote the integrand from (5) and let bl and bu denote
the vector of lower and upper bounds for 0m. One rst transforms the good lattice points
to obtain ui = ui(bu   bl) + bl for i = 1; : : : ; n, and then approximates the integral (5) byQd
j=1(buj   blj)
Pn
i=1 (u

i jy)=n. This approach also allows one to calculate the approximate
maximum in the subsequent optimization step by using the grid point ui corresponding to
max
i2f1;:::;ng
(ui jy). We found that using grids of size 100 in the one-dimensional case and 1597 in
the two-dimensional case provide reliable and computationally ecient results (for integration
and optimization).
The optimization in (4) is a constrained optimization problem because the weights wnext lie in
the (k   1)-dimensional probability simplex. A simple but ecient approach to perform the
optimization is to use a mapping Rk 1 7! Sk and then to employ a standard unconstrained
optimizer, as described in Atkinson, Donev & Tobias (2007, p. 131). To account for the already
allocated patients until an interim analysis, one can optimize 	

nold+Nnextwnext
Nold+Nnext

with respect
to wnext 2 Sk. Due to potential multiple optima in the design surface, one cannot be sure,
whether indeed an optimal design has been found by the optimizer. We thus propose using lower
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bounds of the resulting relative eciencies based on the underlying geometry of the optimization
problem.
To be precise, suppose that the vector w has been found by the optimizer. The following result
gives a lower bound on r(w) = 	(wopt)
	(w) 2 [0; 1], where wopt is the (unknown) true optimal design
at the end of the next stage, accounting for the patients allocated until the current interim
analysis. A proof of the result is given in the Appendix.
Theorem 1. A design w with cm(m) = rbm(m) 2 Range(Mm(m;w)), m = 1; : : : ;M ,
minimizes 	(w) with respect to wnext, where w =
Nold+Nnextwnext
Nold+Nnext
, if and only if there exist
generalized inverses G1; : : : ;Gm of Mm(m;w), such that the inequality
h(d;w) =
PM
m=1 m
(gTm(d;m)Gmcm(m))
2
cTm(m)Gmcm(m)PM
m=1 m
cm(m)G
T
mMm(m;wnext)Gmcm(m)
cTm()Gmcm()
 1
is satised for all d 2 fd1; : : : ; dkg. Moreover, the eciency of any design w can be bounded
from below by
r(w)  1
k(w; )
 1
h(w)
; (7)
where  = Nold
Nold+Nnext
, h(w) = min
G1;:::;Gm
max
d2fd1;:::;dkg
h(d;w),
k(w; ) =
"
1 + (1  ) min
G1;:::;Gm
max
v2Sk
MX
m=1
m
cTm(m)G
T
m(Mm(m;v) Mm(m;wnext))Gmcm()
cTm(m)Gmcm(m)
# 1
;
and the minimum is taken over all generalized inverses G1; : : : ;Gm of the matrices M 1(1;w);
: : : ;MM(M ;w).
When the matrices M 1(1;w); : : : ; MM(M ;w) are invertible, h
(w) is just the maximum of
h(d;w) over the k doses and straightforward to calculate (and so is the lower bound on r(w)).
This lower bound is useful in several respects: We do not need to know the actual optimal design
wopt in order to calculate the lower bound. If the lower bound for our calculated design w
 is
equal to 1, we know that w is the optimal design. Otherwise, we have a conservative estimate
on how much percent o one would be when using w. The bound based on k(w; ) is sharper,
however harder to implement.
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If one does not use a fully Bayesian approach for the nal analysis, one typically has to t non-
linear regression models to the data. When there are only few doses available, as it is often the
case in drug development practice, calculating the ML estimate may be dicult. One way to
simplify the problem is by exploiting the fact that 0 and 1 enter the model function linearly
in (1). We thus apply the nonlinear optimization only on the non-linear parameters 0m, similar
in spirit to Golub & Pereyra (2003). Using the Frisch-Waugh-Lovell theorem (Baltagi 2008,
ch. 7) we can recalculate the residual sum of squares eciently, without the need to solve the
full least squares problems in each iteration of the non-linear optimization (this eect becomes
even more important when there are additional linear covariates in the model equation, such as
gender, baseline values, etc.). In addition, we impose bounds on the non-linear parameters 0m
to guarantee the existence of the least squares estimate (Seber & Wild 1989, chapter 12). As
mentioned in Section 3.2.1, such bounds are not a severe restriction in practice and ensure that
the optimization problem is well-posed.
4 Asthma study re-visited
In this section we re-visit the asthma case study from Section 2 and address the four open
design questions using the proposed methodology from Section 3. To this end, we investigated
in an extensive simulation study the operating characteristics for dierent design options and
parameter congurations.
4.1 Design of simulation study
We generated normally distributed observations according to the dose-response models given
in Table 1 with  = 350 mL. To investigate the robustness of the proposed methods, we also
simulated from a linear model (with baseline 100 mL and maximum eect 300 mL) that was not
included in the candidate model set. The total sample size was xed at 300 (constraint imposed
by the clinical team). To evaluate the benet of including additional doses we compared two
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design options, one with the four active doses 2.5, 10, 20, 50 (plus placebo) and another one with
the seven active doses 0.5, 1, 2.5, 5, 10, 20 and 50 (plus placebo). In addition, we evaluated the
benet of additional interim analyses by varying their number from 0 (= no interim analysis)
to 9, where the interim looks were chosen equally spaced in time. In all cases, we assumed a
balanced rst stage design. The designs from the second stage onwards were determined using
the observed data according to the algorithm from Section 3.3. When the MED did not exist
for certain models at an interim analysis, they were removed from the model set and the model
probabilities were accordingly re-weighted. When the MED did not exist for any model, balanced
allocations were used for the next cohort of patients.
For the nal analysis we employed the MCP-Mod procedure from Bretz, Pinheiro & Branson
(2005). A potential dose-response signal was assessed using model-based multiple contrast tests
based on the candidate model set from Table 1. Subsequently, if there were signicant models,
the dose-response model with lowest Akaike Information Criterion (AIC) among the signicant
models was chosen to estimate the MED.
The methodology from Section 3 was applied with uniform prior probabilities for the dierent
models. We further assumed a-priori distributions with mean 100 and variance 100000 for the
placebo eect and mean 300 and variance 100000 for the maximum treatment eect, which were
then transformed into the linear parameters for all dose-response models. The mode of the
marginal distribution for 2 was chosen as 3502 with d = 4, resulting in an innite variance.
For the non-linear parameters we assumed beta distributions (or products thereof) with mode
equal to the values specied in Table 1 and S = 3. The parameter bounds were chosen to
ensure that all reasonable dose-response shapes remained included within the bounds. That is,
we chose 2 2 [0:05; 75] for the Emax models, (2; 3) 2 [0:5; 4]  [0:5; 4] for the beta models
and (2; 3) 2 [0:05; 75]  [0:5; 25] for the the logistic model. For each scenario we used 5000
simulation runs.
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4.2 Simulation results
For the chosen standard deviation of  = 350 mL the power of the MCP-Mod procedure to
detect a dose-response signal was almost always close to 1. Thus, the MCP-Mod procedure was
essentially reduced to choosing the non-linear model with lowest AIC value under the constraint
that only models with signicant contrast test statistics were included in the model selection
step. Simulations with  values larger than 350 mL indicated that the power quickly dropped
to lower levels (results not shown here), although the estimation results remained qualitatively
similar to the ones shown below.
In Figure 3 we display the mean absolute estimation error for the MED estimates against the
number of interim analyses. In all scenarios one observes a benet from adapting, while most
of the improvement is already achieved after 1, 2 or 4 interim analyses. The largest relative
improvement (comparing no adaptations vs 9 adaptations) can be observed for the Logistic1 and
the Beta model, particularly in the case of 7 active doses. The worst relative improvement can
be observed for the Logistic2 model, which overall has the largest absolute estimation error. This
is not surprising, because even when adapting one cannot achieve a good design for this model,
as there are no doses available for administration in the interval (20; 50) containing the MED,
see also Figure 1. It is remarkable to see that adaptation also works if the true model is a linear
model, although it is not included in the candidate model set. It seems that other models in the
candidate set are able to capture the shape of a linear model reasonably well.
The comparison between 4 and 7 active doses is not entirely clear. If no interim analyses are
performed, it seems that the design with a balanced allocation across the 4 active doses is
slightly better than the design with a balanced allocation across all 7 active doses. If one decides
to adapt, however, it seems benecial in some cases to have more doses available, particularly if
many interim analyses are performed, while in other cases 4 active doses are sucient.
To illustrate how adaptation changes the allocation of patients to the dierent doses, we display
in Figure 4 the average patient allocations for the Emax2 model after 1, 2, 4, and 9 interim
analyses and with 7 available active doses. The adaptive design tends to allocate more patients
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Figure 3: Mean absolute estimation error for MED estimation.
both on placebo and nearby the actual MED. This is intuitively plausible, as the MED estimate
depends on the precision of the estimated placebo eect as well as of the estimated function f(:)
around the true MED. It also follows from Figure 4 that for a large number of interim analyses
the overall allocation is close to the one under a locally optimal design for the Emax2 model,
with the variability in the allocations due to the uncertainty both in estimating the correct model
and the model parameters at the interim analysis. Similar conclusions also hold for other models
than the Emax2 model (not reported here).
We now investigate to which extent the precision gain observed in Figure 3 translates into sample
size savings when performing an adaptive design. In other words, how many additional patients
are required for a non-adaptive, balanced design to achieve a similar estimation error as with
an adaptive design using 300 patients. We again considered the Emax2 model and iterated the
total sample size until the mean absolute estimation error was approximately 4 (which is the
mean absolute estimation error obtained after 9 interim analyses, as seen in Figure 3). For both
design options with 4 and 7 active doses this was achieved after roughly 500 patients. Thus,
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using a non-adaptive, balanced design one would need 200 additional patients to achieve a similar
precision in MED estimation as compared to an adaptive design using 300 patients.
The adaptive design benets observed so far depend on several input parameters, such as the
starting design for the rst stage. One may argue that starting with a bad design that allocates
patients at the \wrong" doses may be improved by adapting at one or more interim looks. On
the other hand, starting with a good design may lead to adaptations following random noise at
the interim analyses. To illustrate this eect, we report the results for the simulations under the
Logistic1 model (similar results were also obtained for other models and scenarios, but are not
reported here). We used four dierent starting designs. We used w = (0:35; 0:03; 0:22; 0:35; 0:05)
and w = (0:35; 0:02; 0:02; 0:02; 0:02; 0:20; 0:30; 0:07) as good starting designs with 4 and 7 active
doses, respectively. These designs work well because they allocate patients on placebo and
around the MED, while keeping some mass on the remaining doses. In addition, we used w =
(0:1; 0:3; 0:05; 0:05; 0:5) and w = (0:1; 0:2; 0:22; 0:02; 0:02; 0:02; 0:02; 0:4)0 as bad starting designs,
as they have relatively few patients on placebo and around the MED. It follows from Figure 5
that substantial improvements are possible when using bad starting designs. On the other hand,
for good starting designs no benet is achieved by adapting and the performance may even
deteriorate, because the possibility of adapting may lead one to deviate from the already good
starting design. In practice, one does not know whether an employed design is good or bad, but
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one should keep in mind the possibility that adaptive designs will not always improve upon the
initial design.
To further investigate the robustness of the proposed methods we repeated the simulation study
from Figure 3 by increasing the standard deviation to 450 mL and 700 mL. The overall results
remain similar, but with increased absolute estimation errors. However, the relative benet of
9 interim analyses vs. no adaptation decreases slightly. Due to the larger noise, one obtains
less reliable information at an interim analysis and one may end up with a worse design for
the next stage. We also investigated the eect of prior misspecication. For this purpose we
misspecied the prior means or prior modes by adding or subtracting 20% of the true value, but
leaving the variability (variance of baseline and maximum eect and the value S for the beta
distribution) unchanged as in the original simulations. The results are largely identical to those
presented in Figure 3, indicating that the proposed methods are robust under moderate prior
misspecications.
4.3 Conclusion for asthma study
Many more simulations than presented above were conducted at the planning stage of the asthma
study to address the four questions stated in Section 2. Regarding question (A) the team felt
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that the potential benets of conducting an adaptive design (more precise MED estimation)
outweighed the additional logistical requirements, especially in view of the perceived sample size
gain of 100 - 200 patients when compared to a xed-sample study designed to achieve a similar
precision. For question (B) it was decided to have one interim analysis: Based on Figure 3 and
other simulation results, the potential further reduction of the mean absolute estimation error
with two or more interim analyses was perceived as too small to justify the additional logistical
complexity.
For similar reasons, the team decided against having all seven actives doses from the beginning
on (question (C)). Instead, it was decided to allocate 150 patients equally across the fours active
doses 2.5, 10, 20, 50 (plus placebo) in the rst stage. Once the interim results are available
and analyzed with the methods from Section 3, however, patients could be allocated to all seven
active doses (or a subset thereof) in the second stage. For practical reasons, the clinical team
decided to incorporate constraints on the minimum number of patients allocated per dose in the
second stage: If the algorithm would allocate less than 5% of the patients on a certain dose, that
dose would be dropped altogether and the corresponding patients re-allocated to the remaining
doses.
5 Discussion
Motivated by a dose nding study in moderate persistent asthma, we described a response-
adaptive approach that addresses common challenges encountered in dose-nding studies: mul-
tiple objectives, model uncertainty, and large variability. When planning an adaptive dose-nding
design it is important to realize that it may not always be better than a non-adaptive design.
It is necessary to employ a factored view as many parameters may impact the performance of
a study design. Often, an unbalanced xed-sample design derived from optimal design theory
might already provide benet over a balanced xed-sample design and adaptation may not bring
further advantages, particularly if the variability is large (which is common in practice). Thus,
adaptive designs are promising in situations where the initial design is not good and/or interim
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data have low variability. In practice one never knows how good the initial design will be, before
trial start, and adaptive designs may guard against bad initial designs. However, the benets of
adaptive dose-nding designs have to be balanced against the increased logistical requirements
to implement processes for repeated data collection, cleaning and analyses, to maintain trial
integrity and validity, and to overcome potential challenges in drug manufacturing and supply.
In this paper we focused on designs based on the compound optimality criterion (4) to address
model uncertainty and to minimize the variance of [MED. The criterion depends on the param-
eters of the dierent dose-response models as well as on the model probabilities and we used a
Bayesian approach to continuously update parameter values and model probabilities based on
the information accrued in the trial. The approach was implemented based on optimization and
numerical quadrature, so that computationally intensive Markov Chain Monte Carlo techniques
could be avoided. Computational eciency is of extreme importance as the frequentist operating
characteristics of any adaptive design methodology needs to be evaluated in extensive simulations
under multiple scenarios.
The proposed method can be extended immediately if alternative optimality criteria (such as
EDp- or D-optimal designs, see Dette, Kiss, Bevanda & Bretz (2010)) or mixtures thereof are
of interest. Alternatively, optimal discrimination designs could be applied that allow one to
dierentiate among several candidate nonlinear regression models (Atkinson & Fedorov (1975),
Dette & Tito (2009)). It would be interesting to address multiple objectives by considering
dierent optimality criteria at dierent stages, such as using a model discrimination design in
earlier stages, and MED-optimal design in later stages. This will be investigated in future
research, but see Dragalin et al. (2010) for initial results.
The R code used for the simulations is largely available with the DoseFinding package in R
Bornkamp, Pinheiro & Bretz (2010). Currently the package includes functions for calculating
and updating optimal designs and an implementation of the MCP-Mod procedure. The Bayesian
updating step is available from the authors upon request.
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Appendix: Proof of Theorem 1
Proof of Theorem 1. Obviously the rst part of the Theorem follows from the lower bound
(7) on the eciency. For a proof of (7) let  = Nold=(Nold + Nnext) 2 (0; 1) and note that the
total information of the experiment in the mth model is given by
Mm(;wold;wnext) = Mm(m;wold) + (1  )Mm(m;wnext) (8)
where we collect in the vector  = (1; : : : ;M) the parameters of the dierent models. Dene
a block diagonal matrix by
M (m;wold;wnext) = diag(M 1(m;wold;wnext); : : : ;MM(M ;wold;wnext)) (9)
(all other entries in this matrix are 0) and similarly
K = diag(c1(1); : : : ; cM(M));
where the vector cm() is given by cm() = rbm();m = 1; : : : ;M . For a design wnext, such
that cm() 2 Range(Mm(m;wold;wnext) (m = 1; : : : ;M) we consider the information matrix
CK(M (;wold;wnext)) = (K
TM
 
(;wold;wnext)K)
 1
= diag((cT1 (1)M
 
1 (1;wold;wnext)c1(1))
 1; : : : ;
(cTM(M)M
 
M(M ;wold;wnext)cM(M))
 1):
Note that the optimal design maximizes
	 1(wnext) =
Nold +Nnext
2
 (CK(M (;wold;wnext))
=
Nold +Nnext
2
MY
m=1
(cTm()M
 
M(m;wold;wnext)cm())
 m ;
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where the last identity denes the criterion  and we have used the notation (diag(1; : : : ; M)) =QM
m=1 
m
m . Now according to Theorem 1 in Dette (1996) a lower bound for the eciency of the
design wnext
r(w) =
  1(w)
  1(wopt)
=
(Ck(M (;wold;wnext))
maxv2Sk (CK(M (;wold;v))
is obtained as
e =
h
min
G
max
A2A
tr
n
GKCK(M (;wold;wnext))ECK(M (;wold;wnext))K
TGTA
oi 1
where the minimum is taken over the set of all generalized inverses of the matrixM (;wold;wnext)
and the set A is dened by
A = fM (;wold;v) j v 2 Skg
and the matrix E is given by
E = diag(1c
T
1 ()M
 
1 (1;wold;v)c1(); : : : ; Mc
T
M()M
 
M(M ;wold;v)cm):
Therefore, observing the identity
Mm(m;wold;v) =Mm(m;wold;wnext) + (1  )(M (m;v) M (;wnext));
we obtain
e =
"
1 + (1  )min
Gm
max
v2Sk
MX
m=1
m
cTm(m)G
T
m(Mm(m;v) Mm(m;wnext))Gmcm()
cTm(m)Gmcm(m)
# 1

24 min
G1;:::;Gm
max
d2fd1;:::;dkg
PM
m=1 m
(gTm(d;m)Gmcm(m))
2
cTm(m)Gmcm(m)PM
m=1 m
cTm(m)G
T
mMm(m;wnext)Gmcm(m)
cTm(m)Gmcm(m)
35 1 ;
where we have used the inequality
[1 + (1  )(A B)] 1  [A
B
] 1
for A  B  0, (1  )B  1 and standard arguments in design theory. 
25
References
Atkinson, A. C., Donev, A. N. & Tobias, R. D. (2007) Optimum Experimental Design,
with SAS, Oxford University Press, Oxford.
Atkinson, A. C. & Fedorov, V. V. (1975) Optimal design: Experiments for discriminating
between several models, Biometrika 62, 289{303.
Baltagi, B. H. (2008) Econometrics, 4th edition, Springer, Berlin.
Berger, J. & Pericchi, L. (1996) The intrinsic Bayes factor for model selection and predic-
tion, Journal of the American Statistical Association 91, 109{122.
Biedermann, S., Dette, H. & Pepelyshev, A. (2006) Some robust designs for percentile
estimation in binary response models, Canadian Journal of Statistics 34, 603{622.
Bornkamp, B. (2006) Comparison of model-based and model-free approaches for the analysis
of dose-response studies, Diploma Thesis, Fakultat Statistik, Technische Universitat Dort-
mund, available under: http://www.statistik.uni-dortmund.de/~bornkamp/diplom.pdf.
Bornkamp, B., Pinheiro, J. & Bretz, F. (2010) DoseFinding: Planning and Analyzing
Dose Finding experiments, R package version 0.1-1.
Bretz, F., Hsu, J. C., Pinheiro, J. C. & Liu, Y. (2008) Dose nding - a challenge in
statistics, Biometrical Journal 50, 480{504.
Bretz, F., Pinheiro, J. & Branson, M. (2005) Combining multiple comparisons and mod-
eling techniques in dose-response studies, Biometrics 61(3), 738{748.
Chaloner, K. & Verdinelli, I. (1995) Bayesian experimental design: A review, Statistical
Science 10, 273{304.
Chatfield, C. (1995) Model uncertainty, data mining and statistical inference, Journal of the
Royal Statistical Society. Series A (Statistics in Society) 158, 419{466.
26
Cook, R. D. & Wong, W. K. (1994) On the equivalence of constrained and compound
optimal designs, Journal of the American Statistical Association 89, 687{692.
Dette, H. (1996) Lower bounds for eciencies with applications, in E. Brunner & M. Denker
(eds.), Research Developments in Probability and Statistics: Festschrift zum 65sten Geburt-
stag von M.L. Puri, VSP Utrecht, pp. 111{124.
Dette, H., Bretz, F., Pepelyshev, A. & Pinheiro, J. C. (2008) Optimal designs for dose
nding studies, Journal of the American Statistical Association 103, 1225{1237.
Dette, H., Kiss, C., Bevanda, M. & Bretz, F. (2010) Optimal designs for the emax,
log-linear and exponential models, Biometrika , (in press).
Dette, H. & Titoff, S. (2009) Optimal discrimination designs, Annals of Statistics 37,
2056{2082.
Dragalin, V., Bornkamp, B., Bretz, F., Miller, F., Padmanabhan, S. K., Patel,
N., Perevozskaya, I., Pinheiro, J. & Smith, J. R. (2010) A simulation study to
compare new adaptive dose-ranging designs, Statistics in Biopharmaceutical Research , (in
press).
Dragalin, V., Hsuan, F. & Padmanabhan, S. K. (2007) Adaptive designs for dose-nding
studies based on sigmoid emax model, Journal of Biopharmaceutical Statistics 17, 1051{
1070.
Draper, D. (1995) Assessment and propagation of model uncertainty, Journal of the Royal
Statistical Society. Series B (Methodological) 57, 45{97.
Fang, K.-T. & Wang, Y. (1994) Number theoretic methods in statistics, Chapman and Hall,
London.
Fedorov, V. & Leonov, S. (2001) Optimal design of dose response experiments: A model-
oriented approach, Drug Information Journal 35, 1373{1383.
Golub, G. & Pereyra, V. (2003) Separable nonlinear least squares: the variable projection
method and its applications, Inverse Problems 19, R1{R26.
27
Hjorth, J. S. U. (1994) Computer intensive statistical methods: validation model selection and
bootstrap, Chapman and Hall, New York.
Kass, R. & Raftery, A. (1995) Bayes factors, Journal of the American Statistical Association
90, 773{795.
King, J. & Wong, W. K. (2004) Optimal designs for the power logistic model, Journal of
Statistical Computation and Simulation 74, 779{791.
Lauter, E. (1974) Experimental design in a class of models, Mathematische Operations-
forschung und Statistik 5, 379{398.
Miller, F., Guilbaud, O. & Dette, H. (2007) Optimal designs for estimating the interesting
part of a dose-eect curve, Journal of Biopharmaceutical Statistics 17, 1097{1115.
Muller, P., Berry, D. A., Grieve, A. P. & Krams, M. (2006) A Bayesian decision-
theoretic dose-nding trial, Decision Analysis 3, 197{207.
O'Hagan, A. (1995) Fractional Bayes factors for model comparison (with discussion), Journal
of the Royal Statistical Society B 56, 99{138.
O'Hagan, A. & Forster, J. (2004) Kendall's Advanced Theory of Statistics, Volume 2B:
Bayesian Inference, 2nd edition, Arnold, London.
Pinheiro, J. C., Bornkamp, B. & Bretz, F. (2006) Design and analysis of dose nding
studies combining multiple comparisons and modeling procedures, Journal of Biopharma-
ceutical Statistics 16, 639{656.
Pukelsheim, F. (1993) Optimal Design of Experiments, Wiley, New York.
Ruberg, S. J. (1995) Dose response studies. I. Some design considerations, Journal of Biophar-
maceutical Statistics 5(1), 1{14.
Seber, G. & Wild, C. (1989) Nonlinear Regression, Wiley, New York.
van der Vaart, A. (1998) Asymptotic Statistics, Cambridge University Press.
28
Wathen, J. K. & Thall, P. F. (2008) Bayesian adaptive model selection for optimizing group
sequential clinical trials, Statistics in Medicine 27, 5586{5604.
Wu, C. F. J. (1988) Optimal design for percentile estimation of a quantal response curve, in
Optimal Design and Analysis of Experiments, Elsevier, pp. 213{222.
Zhou, X., Joseph, L., Wolfson, D. B. & Belisle, P. (2003) A Bayesian A-optimal and
model robust design criterion, Biometrics 59, 1082{1088.
Zhu, W. & Wong, W. K. (2000) Multiple-objective designs in a dose-response experiment,
Journal of Biopharmaceutical Statistics 10, 1{14.
Zhu, W. & Wong, W. K. (2001) Bayesian optimal designs for estimating a set of symmetric
quantiles, Statistics in Medicine 20, 123{137.
29
 
 
 
